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Abstract 
 
Gene expression of the cardiac isoform of acetyl-CoA carboxylase (ACCβ) is induced 
in a glucose-dependent manner. ACCβ produces malonyl-CoA, a potent inhibitor of 
mitochondrial fatty acid uptake. Previous studies show that increased flux through the 
hexosamine biosynthetic pathway (HBP) under hyperglycaemic conditions may 
contribute to the development of insulin resistance.  In light of this, we hypothesised 
that increased HBP flux induces cardiac ACCβ gene expression thereby contributing 
to the onset of insulin resistance.  
 
We tested our hypothesis by transiently transfecting cardiac-derived rat H9c2 
myoblasts with a 1,317 bp human ACCβ promoter-luciferase construct (pPIIβ-1317) 
and an expression construct encoding the rate-limiting step of the HBP i.e. glutamine: 
fructose 6-phosphate amidotransferase (GFAT).  Overexpression of GFAT increased 
ACCβ gene promoter activity by 75 ± 23% versus controls (n=6, p<0.001).  When co-
transfection experiments were repeated in the presence of varying concentrations of 
L-glutamine (0 mM, 4 mM, 8 mM), a substrate for the HBP, ACCβ promoter activity 
was dose-dependently increased.  To further corroborate these findings, we 
employed two inhibitors of GFAT, i.e. 40 µM azaserine and 40 µM 6-diazo-5-oxo-L-
norleucine were administered to transfected cells for a period of 24 hours.  Here both 
azaserine and 6-diazo-5-oxonorleucine attenuated ACCβ gene promoter activity.   
 
In agreement, co-transfections with two dominant negative GFAT constructs also 
diminished ACCβ gene promoter activity.  We next inhibited two enzymes of the HBP 
acting downstream of GFAT, i.e. O-GlcNAc transferase and O-GlcNAcase using 
alloxan (0.1 mM, 1 mM and 2 mM) and streptozotocin (5 mM and 10 mM), 
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respectively, for a period of 24 hours.  Addition of alloxan attenuated ACCβ gene 
promoter activity by 35.6 ± 1.9% (n=16, p<0.001) and streptozotocin increased 
activity by 32 ± 12% (n=12, p<0.001).  We also investigated USF1 and USF2 as 
transcriptional regulatory candidates for HBP-induced ACCβ promoter regulation.  
Our data implicates USF2 as an important transcriptional regulator of HBP-induced 
ACCβ promoter regulation. 
 
In summary, this study demonstrates that increased flux through the hexosamine 
biosynthetic pathway induces ACCβ gene promoter activity. We further propose that 
such an induction would reduce cardiac fatty acid oxidation, thereby leading to 
intracellular lipid accumulation due to a mismatch between sarcolemmal FA uptake 
and mitochondrial FA oxidation in the insulin resistant setting (i.e. hyperlipidaemia). 
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Opsomming 
 
Geen uitdrukking van die kardiale isoform asetiel-KoA karboksilase (ACCβ) word in ‘n 
glukose afhanklike wyse geïnduseer.  ACCβ produseer maloniel-KoA, ‘n kragtige 
inhibeerder van mitochondriale vetsuuropname.  Vorige studies toon aan dat 
verhoogde fluks deur die heksosamien biosintestiese weg (HBW) onder 
hiperglukemiese toestande bydra tot die ontwikkeling van insulienweerstand.  In die 
lig hiervan, word daar gehipotetiseer dat verhoogde HBP fluks kardiale ACCβ 
geenuitdrukking induseer en so bydra tot die ontstaan van insulienweerstand.   
 
Ons hipotese is getoets deur die kardiale afkomstige rot H9c2 mioblaste met ‘n 1.317 
bp mens ACCβ-lusiferase promotor konstruk (pPII-1317) te transfekteer en ‘n 
uitdrukking te konstrueer wat die tempo bepalende stap van HBP i.e. glutamien: 
fruktose-6-fosfaat amidotransferase (GFAT) kodeer.  Ooruitdrukking van GFAT 
verhoog ACCβ geenpromotor aktiviteit deur 75 ± 23% teenoor kontrole (n=6, 
p<0.001).  Die herhaling van ko-transfeksie eksperimente is herhaal in die 
teenwoordigheid van variëerbare L-glutamienkonsentrasies (0 mM, 4 mM, 8 mM), ’n 
substraat vir die HBP, ACCβ promotor aktiwiteit is dosisafhanglik verhoog.  Om die 
bevindinge verder te staaf, is twee inhibeerders van GFAT, i.e. 40 µM azaserien en 
40 µM 6-diazo-5-oxo-L-norleusien aan transfeksie selle toegedien vir ’n tydperk van 
24 uur.  Beide azaserien en 6-diazo-5-oxo-L-norleusien verlaag ACCβ geenpromotor 
aktiwiteit. 
 
In ooreenstemming met die bogenoemde het ko-transfeksies met twee dominante 
negatiewe GFAT konstrukte ook ACCβ geenpromoter aktiwiteit verminder.  Die 
volgende stap is om twee ensieme van die HBP wat stroomaf van GFAT aktief is, vir 
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‘n periode van 24 uur te inhibeer i.e. O-GlcNAc transferase en O-GlcNAcase deur 
alloxan (0.1 mM, 1 mM en 2 mM) and streptozotosien (5 mM en 10 mM) 
onderskeidelik vir ‘n 24 uur periode te gebruik.  Toevoeging van alloxan het die ACCβ 
geenpromotor aktiwiteit by 35.6 ± 1.9% (n=16, p<0.001) verlaag en streptozotosien 
aktiwiteit verhoog by 32 ± 12% (n=12, p<0.001).  Ons het ook die USF1 en USF2 as 
transkripsie regulerings kandidate vir HBP-geïnduseerde ACCβ promotor regulering 
ondersoek.  Ons data impliseer dat USF2 as ‘n belangrike transkripsie reguleerder 
van HBP-geïndiseerde ACCβ promotor regulering is. 
 
Samevattend het hierdie studie demonstreer dat verhoogde fluks deur die 
hexosamien biosintetiese weg ACCβ geenpromotor aktiwiteit induseer. Ons stel 
verder voor dat hierdie induksie die kardiale vetsuuroksidasie verlaag wat daartoe lei 
dat intrasellulêre lipied akkumulasie as gevolg van onparing tussen sarkolemma 
vetsuuropname en mitochondriale vetsuuroksidasie in ’n insulien weerstandige 
situasie (i.e. hiperlipidaemia). 
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Chapter 1 
Introduction 
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1.1 Epidemiology 
 
Obesity is defined as an excess of body fat which accumulates in adipose 
tissue, associated with increased fat cell size and number (68). Obesity has 
become more prevalent world wide, resulting in an increase in related 
diseases such as type-2 diabetes. Although obesity is especially common in 
industrialised countries, its prevalence is also dramatically increasing in 
developing countries such as South Africa (4). The movement of populations 
from a rural type to a more “western-based” lifestyle with its increased 
availability of high-calorie foods is a key factor that has lead to a higher 
incidence of obesity. It is predicted that ~300 million people worldwide will be 
diagnosed with type-2 diabetes by 2025 (122, 126).  
 
Most patients who are obese develop insulin resistance which is 
characterised as an impairment of insulin to mediate glucose uptake and 
metabolism by muscle and adipose tissue. Cardiovascular disease is the 
primary cause of mortality in obese individuals and in patients diagnosed with 
type-2 diabetes mellitus (60, 68, 112, 127). Although the heart plays a small 
role in the development of insulin resistance throughout the whole body, 
cardiovascular complications are the main causes of death in insulin resistant 
obese and type-2 diabetes patients (23). Diabetes mellitus is a cluster of 
metabolic perturbations characterized by high blood glucose levels or 
hyperglycaemia, which result from defects in insulin secretion, or action, or 
both. Diabetes mellitus, can easily be identified with high glucose levels found 
in urine and excessive muscle loss (121). 
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 2 
South Africa has a unique, heterogeneous population originating from a 
diverse range of ethnic backgrounds. The ~ 46 million individuals that reside 
in South Africa largely consist of African (79%), Caucasoid (9.6%), mixed 
ancestry (“coloured”) (8.9%) and Indian backgrounds (2.5%). More recently, 
migrants from other African countries have also settled in South Africa. This 
diverse cultural and ethnic diversity makes it difficult to elucidate trends with 
respect to changes in diet and health behaviours of the entire population. 
There are also limited studies performed to assess the prevalence of 
metabolic syndrome (a precursor to obesity and diabetes) in South Africa. 
However, recent data show that mortality rates from ischaemic heart disease 
among whites, coloureds and Indians were found to be more than 2x the rate 
for blacks, while stroke death rates among blacks and coloureds were double 
compared to whites (Table 1).  
 
There are many sociological implications why the prevalence of 
cardiovascular diseases has become more common. For example, for the 
black community, the highest incidences of obesity are observed in black 
women (4). This may, in part, depend on the cultural background in the black 
population where obesity is often regarded as a reflection of health and wealth 
(4).  
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Table 1: Age-standardised mortality rates per 100, 000 population, South 
Africa (112). 
 Ischaemic 
heart disease 
Stroke Hypertensive 
heart disease 
Diabetes 
Black 70 143 88 56 
White 230 72 10 22 
Coloured 171 139 37 59 
Indian 392 392 29 103 
South Africa 123 124 68 54 
 
Other associated lifestyle risk factors may also influence the epidemiology of 
cardiovascular diseases. Risk factors such as physical inactivity, increased 
smoking, hypertension and hypercholesterolemia may play an important role 
in the increase in cardiovascular disease and type-2 diabetes (112, 131). For 
example, although measures were adopted to reduce smoking (higher retail 
prices and a smoking ban) a recent South African report found that the 
prevalence of young smokers (14 years) increased by 30% (112). The survey 
was performed from 1998 to 2003 among a population of 15,124 school 
children in South Africa. Furthermore, the prevalence of sedentary behaviour 
has increased in recent years (112). Together these data highlight the 
increased burden of diabetes and cardiovascular diseases faced by 
developing nations such as South Africa.  
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 4 
In light of this our laboratory has begun to investigate the basic mechanisms 
underlying the development of diabetes and cardiovascular diseases. In 
particular, we are focusing on the role of altered metabolism in the 
pathogenesis of type-2 diabetes and heart diseases. For the next part of this 
Introduction, I will now review some basics aspects of the heart’s metabolism 
and thereafter focus on my particular interest, i.e. the hexosamine 
biosynthetic pathway. 
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 5 
1.2 Metabolism of the heart 
 
The heart pumps blood for the complete lifespan of an individual. This 
constant workload demands a high capacity for energy production in the form 
of adenosine triphosphate (ATP), produced by the mitochondria of the heart. 
In terms of its fuel substrate preferences, the heart is like an omnivore, 
utilising fatty acids, glucose, lactate and ketone bodies and is able to switch 
between either one depending on substrate availability (23). The normal adult 
mammalian heart prefers fatty acids as a fuel source, i.e. obtaining ~70% of 
its energy from fatty acid oxidation with the remainder provided by glucose 
and lactate (23). In the foetal heart carbohydrates are major substrates.  
 
The heart utilises ketone bodies as a fuel source during fasting conditions. 
Metabolism of ketones generates NADH2 and FADH2 which can be used to 
generate energy by the electron transport chain (36). It has been shown that 
ketone bodies are able to suppress cardiac fatty acid oxidation in diabetes 
(46).  
 
Studies have shown that in conditions of increased exercise, hypoxia, and 
anoxia excess pyruvate from glycolysis is converted into lactate (37). Brooks 
et al. (2000) introduced the hypothesis of a ‘’lactate shuttle’’ (9). This 
hypothesis proposes that lactate formation and its distribution throughout the 
body can act as a mechanism to coordinate metabolism in different tissues. It 
is known that during intense exercise lactate flux can exceed glucose flux (9, 
37). 
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1.2.1. Fatty acid metabolism 
 
Fatty acids have four major physiological roles in metabolism. Firstly, it forms 
building blocks in the formation of phospholipids and glycolipids; secondly its 
involved in the modification of proteins that are targeted to the cell membrane; 
thirdly it can serve as hormones and intracellular messengers; and finally fatty 
acids are utilised as fuel substances (113).  Fatty acids are stored as 
triacylglycerol in adipose tissue until it is needed, i.e. then to be broken down 
by lipolysis (113).  
 
Long-chain fatty acids (LCFAs) enter the circulation in two forms, either in a 
complex with albumin or esterified in a lipid core of very-low density 
lipoproteins (VLDLs) and chylomicrons (23, 109, 118). Free fatty acids (FFA) 
are released into the bloodstream by adipose tissue and taken up by non-
adipose tissue via sarcolemmal transporters. It was first believed that LCFAs 
were transported across the sarcolemma into cardiomyocytes by passive 
diffusion, but it is now accepted that most of LCFAs are taken up by 
membrane transporters (40, 72, 73, 92). Two such fatty acid transporters are 
fatty acid translocase, a rat homologue of human CD36 (FAT/CD36) and fatty 
acid binding protein (FABP) (8, 82).  There are also two isoforms of the fatty 
acid transport protein (FATP) family, i.e. FATP1 and FATP6 present in 
cardiomyocytes (110). Both exhibit acyl-CoA synthetase activity. FATP6 is 
found exclusively and in higher abundance in the heart. FATP has been found 
to colocalise with FAT/CD36 and both these LCFA transport proteins act in 
concert with each other.  
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Once inside the cardiac myocyte, LCFAs bind to a cytoplasmic heart-type 
fatty acid binding protein (H-FABP). This protein transports non-esterified 
LCFAs towards a site where they are converted and activated by acyl-
Coenzyme A (acyl-CoA) synthetase to form fatty acyl-CoA. Acyl-CoA binding 
protein (ACBP) then binds to these acyl-CoAs and can either incorporate acyl-
CoA into intracellular lipid pools or shuttle it to the mitochondria to be 
metabolised.  
 
Fatty acyl-CoA is transported into the mitochondria by the action of three 
proteins which function as a complex. At the outer membrane is carnitine 
palmitoyl transferase (CPT1) which catalyses the formation of acylcarnitine 
(23, 29). Connected to CPT1 is carnitine/acylcarnitine transferase (CACT) 
which transports acylcarnitine into the mitochondria. The final enzyme (CPT-
II) is found on the inner mitochondrial membrane and releases acyl-CoA into 
the mitochondrial matrix (23). The process of mitochondrial LCFA uptake is 
regulated by CPT1 which is the rate-limiting enzyme for this process (Figure 
1). 
 
After uptake is complete the acyl-CoAs are oxidised by β-oxidation producing 
acetyl-CoA as a by-product. Acetyl-CoA from β-oxidation enters the citric acid 
cycle to be degraded along with acetyl-CoA from glucose oxidation (23, 34, 
103). The result is the generation of FADH2 and NADH that enter the 
mitochondrial respiratory chain.  In oxidative phosphorylation, ATP synthesis 
is coupled to the flow of electrons from NADH or FADH2 to oxygen by a 
proton gradient across the inner mitochondrial membrane. 
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CPT1 
Free fatty acids 
Sarcolemma 
Acyl- CoA synthetase 
Acyl-CoA 
Fatty acid β-oxidation spiral 
Acyl-CoA 
Acetyl-CoA 
Citric acid cycle FADH2 and NADH 
Figure 1: Diagram of fatty acid metabolism.  
(CPT1: carnitine palmitoyl transferase, ACCβ: acetyl-coenzyme A carboxylase β, LCFA: long-chain 
fatty acid). 
ACCβ 
Acetyl-CoA Malonyl-CoA 
MCD 
FAT/CD36 
LCFA 
Mitochondrion 
Stellenbosch University  http://scholar.sun.ac.za
 9 
A proton gradient is created by pumping protons out of the mitochondrial 
matrix into the inter-mitochondrial membrane space. Thus a proton gradient is 
formed which creates a membrane potential. The protons then flow back into 
the mitochondrial matrix through ATP synthase which drives ATP production 
(113).  
 
Even though LCFAs are utilised for energy production they also play a role in 
the regulation of genes involved in their own metabolic pathway. LCFAs 
induce genes that increase fatty acid oxidation by activating a family of ligand-
activated nuclear receptors called the peroxisome proliferator-activated 
receptors (PPARs) (114, 117). There are three isoforms of PPARs, i.e. 
PPARα, β/δ and γ (114, 117).  PPARα and β/δ are the main isoforms 
expressed in cardiomyocytes and activation of these genes results in an 
increased expression of regulators of fatty acid oxidation and fatty acid 
uptake, i.e. FAT/CD36 and CPT1 (35).  
 
Fatty acid oxidation is regulated depending on fatty acid availability, its uptake 
by mitochondria and by its breakdown. Mitochondrial uptake of long-chain 
fatty acyl units is controlled by CPT1. A key molecule responsible for the 
regulation of CPT1 is malonyl-CoA (66, 68, 89, 100, 111, 130). Malonyl-CoA 
is a potent inhibitor of CPT1 and is produced from acetyl-CoA by an enzyme 
known as acetyl-CoA carboxylase (ACC) (66, 68, 89, 100, 111, 130). Another 
enzyme, malonyl-CoA decarboxylase (MCD) degrades malonyl-CoA into 
acetyl-CoA (28, 111). ACC has two isoforms, ACCα and ACCβ, that have 
different physiological roles based on their distinct subcellular distributions 
(44).  
Stellenbosch University  http://scholar.sun.ac.za
 10 
ACCα is a cytosolic enzyme (molecular mass of 265 kDa) that supplies 
malonyl-CoA to fatty acid synthase (FAS) and is committed to de novo 
lipogenesis (DNL) in many tissues via subsequent nutritional and hormonal 
regulation (3, 39, 44, 61, 97). In contrast, ACCβ (molecular mass of 280 kDa) 
is anchored to the mitochondrial surface via a unique N-terminal domain that 
includes 20 hydrophobic amino acids (1, 2, 39, 44). ACCβ is responsible for 
malonyl-CoA production in the heart. ACCβ overexpression increases 
malonyl-CoA production resulting in a decrease in fatty acid uptake (28, 66, 
89, 100, 111, 130). AMP-activated protein kinase (AMPK) plays and important 
role in the regulation of CPT1 by phosphorylating and inhibiting ACCβ, 
resulting in an increase in fatty acid oxidation. Phosphorylation of ACCβ by 
AMPK is well documented (27, 54). It has been suggested that MCD is also 
phosphorylated by AMPK (27, 101). Therefore, AMPK plays a distinct and 
important role in regulating both malonyl-CoA levels and fatty acid oxidation in 
the heart. 
 
ACCβ is expressed abundantly in heart, skeletal muscle, and liver (1, 61, 87, 
133). ACCβ transcripts contain two species of 5'-UTRs, which contain either 
the sequence of exon 1a or of exon 1b via the alternative usage of two 
promoters, i.e. promoter 1 and promoter 2 (P1 and P2) (87). Exon 1a and 
exon 1b are located ~ 15 kilobases apart in human genome but are both 
connected to exon 2 in mRNA after splicing (87). However, they both use the 
same ATG start codon for translation, which is found in exon 2 and therefore 
the two transcripts encode for the same protein (39, 67, 87). A differential 
regulation of ACCβ gene expression originates from alternative usage of 
promoters, such as P1 and P2 in different tissues. P1 is the sole promoter 
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found in the heart and skeletal muscle of rats, although both P1 and P2 are 
active in human skeletal muscle (87). 
 
In human skeletal muscle and P2 is regulated by myogenic regulatory factors 
(MRFs) (67, 87). MRFs, including Myf5, MyoD, myogenin, and MRF4, are 
basic helix-loop-helix transcription factors involved in myogenic differentiation. 
These factors all recognize the same consensus sequence, i.e. E-box 
(CANNTG) (87). Myogenin and MRF4 play a major role in the expression of 
muscle genes in fully differentiated myotubes, while Myf5 and MyoD have 
been shown to establish the myogenic lineage during embryogenesis (87, 98, 
99, 102, 108). It is important to note that myogenic regulatory factor-binding 
sites found in the human ACCβ P2 are not conserved in rat P2. This would 
contribute to this difference in P2 usage between human and rat skeletal 
muscle (87). 
 
The level of ACCβ is higher in the heart than in skeletal muscle. It is currently 
not known which promoter controls ACCβ expression in the heart. 
Cardiomyocyte-specific transcription factors, such as Csx/Nkx2.5, GATA4, 
MEF2, and eHand have been implicated in cardiac development and cardiac 
gene expression. Unlike in skeletal muscle MRFs have not been shown to be 
involved in this regulation (58, 63, 84, 87, 88).  
 
 
The nucleotide sequence of the cDNA of the human liver ACCβ carboxylase 
has an open reading frame of 7,449 nucleotides that encode 2,483 amino 
acids. The nucleotide sequences and the predicted amino acid sequences 
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from the cDNA of ACCβ, has ~60 and 80% in similarity to that of ACCα, 
respectively. Ser77 and Ser79 have been found to be critical for the 
phosphorylation and of rat ACCα (Ser78 and Ser80 of human ACCα) (1, 87). 
These amino acids are conserved in ACCβ and are represented as Ser219 
and Ser221, respectively. Another phosphorylation site, Ser1200, in rat ACCα 
(Ser1201 of human ACCα) has been found to be absent in ACCβ.  
 
Most of the homology between the amino acid sequences of the human ACC 
isoforms is found downstream of residues Ser78 and Ser81 in human ACCα 
and their equivalent residues in ACCβ, i.e. Ser219 and Ser221 (1). It has 
been suggested that the first 218 amino acids at the N terminus of ACCβ 
represents a unique peptide that could be responsible for the variation 
between the two carboxylases (1). Despite the similarities between these two 
isoforms, studies with rat liver ACCα and ACCβ showed that the two isoforms 
do not cross-react immunochemically (1, 128). It was shown that when the 
amino acid sequences of the human ACCα and ACCβ are aligned, an extra 
142 amino acids can be found in ACCβ (i.e. 426 bp in ACCβ cDNA) (1, 87). It 
is believed that the extra 142 amino acids are involved in controlling the 
localisation of ACCβ in the cell, i.e. to the mitochondrion. 
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1.2.2. Glucose metabolism 
 
The uptake of extracellular glucose by myocytes is mediated by glucose 
transporters (GLUTs). There are two glucose transporters that can be found in 
the heart, i.e. GLUT1 and GLUT4 that are located not only in the sarcolemma 
but also in intracellular storage compartments (6, 23, 48-50, 62, 77, 78, 80, 
105). GLUT1 is the foetal isoform and can be found in less abundance than 
the adult, insulin-stimulated glucose transporter (GLUT4). After glucose has 
entered the cardiomyocytes it is rapidly phosphorylated by hexokinase into 
glucose-6-phosphate.  
 
Once converted to glucose-6-phosphate, glucose can be metabolised in six 
different ways (Figure 2). Firstly, glycogen synthesis can take place and 
glucose-6-phosphate can be converted by glycogen synthase (GS) into 
glycogen for storage. This process is reversible and when required glycogen 
phosphorylase (GP) can convert glycogen back into glucose-6-phosphate 
(113). Some of the glucose-6-phosphate can enter the pentose phosphate 
pathway (PPP) where it has been proposed that xylulose-5-phosphate 
activates a specific isoforms of protein phosphatase 2A which, in turn, 
dephosphorylates the transcription factor carbohydrate response element-
binding protein (ChREBP) (53, 129). In the liver ChREBP translocates from 
the cytosol to the nucleus where it regulates the expression of glycolytic and 
lipogenic enzymes (57).  
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Most of the glucose-6-phosphate enters glycolysis. After the first step of 
glycolysis, phosphoglucose isomerase converts glucose-6-phosphate into 
fructose-6-phosphate (Figure 2). At this point most of the fructose-6-
phosphate continues down the glycolytic pathway where it is converted to 
pyruvate after a long series of steps. However, a small percentage of the 
fructose-6-phosphate is diverted to another pathway responsible for nutrient 
sensing, i.e. the hexosamine biosynthetic pathway (77, 95) (to be discussed in 
more detail later).  
Figure 2: Diagram representing the different pathways of glucose metabolism 
(reproduced from (53)). 
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In the glycolytic pathway, fructose-6-phosphate is converted into fructose-1,6-
bisphosphate by phosphofructokinase which is the rate-limiting enzyme of 
glycolysis (113). The production of pyruvate marks the end of the glycolytic 
pathway. In the absence of oxygen pyruvate can be reversibly converted to 
lactate. Under aerobic conditions pyruvate is transported into the mitochondria 
by pyruvate dehydrogenase (PDH), the rate limiting enzyme of glucose 
oxidation, where it undergoes oxidative decarboxylation into acetyl-CoA (113). 
Acetyl-CoA from glucose metabolism, together with acetyl-CoA from fatty acid 
oxidation, enters the citric acid cycle (Krebs cycle) where it is oxidised to 
carbon dioxide, NADH and FADH2. The NADH and FADH2 produced are then 
used in oxidative phosphorylation to produce ATP after donating their 
electrons to oxygen (113). 
 
Another pathway that utilizes glucose is the polyol pathway. The polyol 
pathway consists of two steps in which glucose is converted to sorbitol and 
then converted into fructose (70). During this process NADPH is converted to 
NADP+ (70). The polyol pathway mainly functions to remove excess glucose 
from glycolysis and then return it to the glycolytic pathway again (70).  
 
The glyoxylate pathway is found mainly in plants and yeast (69). This pathway 
converts acetyl-CoA into oxoloacetate by bypassing the steps in the citric acid 
cycle. It can therefore use fats for the synthesis of carbohydrates (69). 
 
The last pathway that utilises carbohydrates is the biosynthesis of 
oligosaccharides and glycoproteins which are then expressed on the surface 
of cell membranes (20).  
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1.2.3 The Randle cycle 
 
The Randle cycle (named after Philip Randle, its first proposer), which has 
been used to explain the reciprocal relationship between fatty acid oxidation 
and glucose oxidation, has long been implicated as a potential mechanism for 
hyperglycaemia and type-2 diabetes mellitus (106). The Randle cycle states 
that increased fatty acid oxidation causes a decrease in glucose oxidation. 
Thus in the setting of excess FFA and glucose supply (insulin resistant state), 
this is thought to lead to lower glucose uptake and eventually hyperglycaemia 
(106). Here, acetyl-CoA and NADH derived from fatty acid oxidation can 
suppress pyruvate oxidation by inhibiting pyruvate dehydrogenase (33, 85).  
Increased fatty acid oxidation has also shown to result in the inhibition of 
phosphofructokinase and prevent glycolysis. This would increase glucose flux 
through other glucose pathways and result in glucose accumulation (85). 
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1.2.4. Hexosamine biosynthetic pathway 
 
Since the focus of my thesis is on the hexosamine biosynthetic pathway, I will 
now discuss this in more detail. The hexosamine biosynthetic pathway (HBP) 
is a relatively small branch glucose utilising pathway. Only ~3% of the total 
glucose utilised in the cell enters the HBP (77, 95). The pathway is catalysed 
by the rate-limiting enzyme glutamine: fructose 6-phosphate amidotransferase 
(GFAT). During this first step, fructose-6-phosphate and glutamine is 
converted to glucosamine-6-phosphate and glutamate (Figure 3). Thereafter, 
through a series of steps glucosamine-6-phosphate is converted to 
glucosamine-1-phosphate. After the addition of uridine, it is converted into 
uridine diphospho-N-acetylglucosamine (UDP-GlcNAc) and CMP-sialic acid. 
UDP-GlcNAc is the end product of the HBP pathway and also functions as an 
inhibitor of GFAT (12).  
 
 
Glucose 
GFAT 
Glc-6-P F-6-P GlcN-6-P UDP-GlcNAc 
OGT O-GlcNAcase 
O-linked GlcNAc modification 
of nuclear proteins 
Glutamine 
Glucosamine 
Figure 3: Description of the hexosamine biosynthetic pathway. 
(GFAT: glutamine:fructose-6-phosphate amidotransferase, OGT: O-linked β-N-acetylglucosaminyl transferase, 
O-GlcNAcase: β-N-acetylglucosaminidase). 
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UDP-GlcNAc functions as the substrate for O-linked β-N-acetylglucosamine 
transferase (OGT). OGT catalyses the reversible modification of various 
proteins and transcription factors by cleaving UDP from GlcNAc and 
transferring GlcNAc in O-linkage to serine/threonine residues on proteins (12, 
64, 71). O-GlcNAc modification has two novel mechanisms of action. Firstly, 
O-GlcNAc is not elongated into a more complex structure (115). Secondly, it 
has a nucleoplasmic distribution instead of being localised to the cell surface 
like other glycoproteins (45, 52). O-GlcNAc modification has been implicated 
in modulating different mechanisms that include (i) regulating protein 
phosphorylation and function; (ii) altering protein degradation; (iii) altering the 
localisation of proteins; (iv) modulating protein-protein interactions and (v) 
mediating transcription (132). 
 The sites of O-GlcNAc modification are often identical or adjacent to known 
phosphorylation sites, suggesting that “O-GlcNAcation” plays a role in 
regulation of a wide range of pathways (12, 125). It has been shown that O-
GlcNAc regulation can modify proteins in competition with phosphorylation 
(21). In some instances O-GlcNAc and phosphorylation can exist on separate 
and distinct subsets of a protein. For example, c-Myc and RNA polymerase 
both contain threonine or tyrosine sites that can be phosphorylated or 
glycosylated, but although, there has been no proof that the two modifications 
can exist on one protein, there is a possibility that this dual-protein 
modification can occur. In particular, RNA polymerase II exists in two distinct 
forms, i.e. RNA Pol IIA and RNA POL IIO (21, 132). RNA polymerase II 
contains a highly conserved carboxyl-terminal domain (CTD) consisting of 52 
tandem repeats of the consensus sequence Tyr-Ser-Pro-Thr-Ser-Pro-Ser (21, 
24, 26, 132). The CTD of the IIO isoforms is found to be phosphorylated on 
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the serine and threonine residues. In contrast, the IIA isoform is non-
phosphorylated and exhibits extensive O-GlcNAc modification. The existence 
of both O-GlcNAc and phosphorylation site implies a precise regulation of 
protein activity (21).  
 
The modifications of proteins by OGT with O-GlcNAc are also closely 
regulated. Another enzyme responsible for the regulation of O-GlcNAcation is 
β-N-acetylglucosaminidase (O-GlcNAcase). Although OGT is responsible for 
binding O-GlcNAc to serine/threonine residues of proteins, O-GlcNAcase 
functions to remove O-GlcNAc. O-GlcNAc modification is thus regulated in the 
same manner as phosphorylation (Figure 3).  
 
O-GlcNAc modification targets numerous proteins, including transcription 
factors (21, 132). For example, Sp1, an important transcription factor in the 
regulation of several target genes, has been shown to have multiple O-
GlcNAc residues (12, 21, 132). O-GlcNAc has been shown to alter protein 
degradation by two different mechanisms, i.e. (i) by altering the targeting of 
proteins to the proteasome or (ii) by altering the activity of the proteasome. O-
GlcNAc modifies eukaryotic factor (eIF) 2α-p67, Sp1 and estrogen receptor 
(ER)-β prolonging the half-life of these proteins (132). Insulin has been 
reported to increase O-glycosylation and nuclear content of Sp1 (74).   
 
Incubation with high glucose or increasing flux through HBP by 
overexpressing GFAT increased the expression of upstream stimulatory factor 
1 and 2 (USF1 and 2), although these transcription factors are apparently not 
O-GlcNAc modified (12, 123). 
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The gene encoding OGT (O-linked β-N-acetylglucosamine transferase) is 
essential for embryonic and stem cell development in mammals (42), making 
it difficult to produce a transgenic knockout model to investigate HBP 
regulation. Hanover et al. (2005) examined the role of OGT using an ogt-1 
deletion strain of Caenorhabditis elegans (42). This strain exhibited no 
obvious developmental phenotype that was found in homozygous animals 
and could be used successfully as a model for nutrient-driven insulin 
resistance. One of the main findings of this model was that homozygous 
(rat/mouse) lacking ogt-1 had increased levels of glucose and glycogen, 
accompanied by a decrease in fat stores (42). This would imply that the HBP 
was involved in the regulation glycogen synthesis and fatty acid oxidation.  
 
Studies in adipocytes suggest that glucose-induced insulin resistance is 
caused by impaired translocation of insulin-responsive glucose transporters to 
the cell membrane (such as GLUT4) and that an increase in glucose flux 
through the HBP plays a major role in the development of insulin resistance 
(10-12, 79, 96). There are several observations to suggest that the HBP 
increases the development of insulin resistance (6, 13, 18, 47, 48, 55, 77, 81, 
105, 120). Pre-exposure to glucosamine inhibits basal and insulin-stimulated 
glucose transport and decreases insulin-stimulated glycogen synthesis in rat 
muscles without affecting insulin receptor signaling (6, 13, 18, 47, 48, 55, 77, 
81, 105, 120). Increasing HBP flux has been shown to alter glucose uptake 
due to increased O-GlcNAc modification of proteins involved in the regulation 
of the insulin-signaling cascade, i.e. IRS-1, PI-3 kinase and Akt (31, 90, 132). 
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A much lower concentration of glucosamine than glucose is required to elicit 
insulin resistance. The main difference between these two substrates is that 
glucose is utilised by several pathways where glucosamine is utilised only by 
HBP. Glutamine or a mixture of amino acids is also an important requirement 
for the development of glucose-induced insulin resistance of glucose transport 
in adipocytes (55). When transamidases are added to adipocytes treated with 
a mixture of amino acids the effect is reversed (55). 
 
Several studies have shown that by increasing the concentration of 
extracellular glucose and glucosamine, or by increasing glucose uptake by 
overexpressing glucose transporters (GLUTs) results in insulin resistance (6, 
48-50, 62, 77, 78, 80, 94, 105). For example, it was shown that by blocking 
GFAT with pharmacological agents inhibited glucose-mediated insulin 
resistance (77). Moreover, other studies found that GFAT overexpression 
mimicked the effect of treating cells or rats with elevated glucose/glucosamine 
(18, 22, 25, 80). Also by increasing O-GlcNAc levels in mice and in cell culture 
genetically or by pharmaceutical intervention, resulted in insulin resistance (5, 
14, 42, 81, 90, 120). Together these studies therefore support a strong link 
between increased HBP flux and the development of insulin resistance/type-2 
diabetes. 
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1.3. Hypothesis 
 
Since the expression of ACCβ is elevated under hyperglycaemic conditions 
(1-3, 7, 32, 33, 39, 66, 75, 76, 100), we hypothesized that increased HBP 
flux induces cardiac ACCβ gene expression (Figure 4). 
 
We further propose that since this would result in greater malonyl-CoA 
production, less fatty acids will be transported into the mitochondria to be 
oxidised. In the insulin-resistant setting (hyperlipidaemia), failure to oxidise 
fatty acids is predicted to result in an accumulation of intracellular long chain 
fatty acids. This, in turn, could result in deleterious effects, for e.g. cell death 
and contractile dysfunction (68) (Figure 4). 
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Glucose 
Glc-6-P 
F-6-P 
 GFAT 
GlcN-6-P UDP-GlcNAc 
OGT 
O-GlcNAc modification of  
nuclear and cytosolic proteins 
O-GlcNAcase 
ACCβ 
Acetyl-CoA Malonyl-CoA 
MCD 
? 
CPT1 
Mitochondrion 
O-GlcNAc 
Free fatty acids 
Sarcolemma 
Acyl-CoA synthetase 
Acyl-CoA 
Fatty acid β-oxidation Acyl-CoA 
HK 
Carbohydrate metabolism Fatty acid metabolism 
Figure 4: Description of hypothesis.  
(HK: hexokinase, OGT: O-linked β-N-acetylglucosaminyl transferase, ACCβ: acetyl-coenzyme A carboxylase, MCD: 
malonyl-CoA decarboxylase, CPT1: carnitine palmitoyl transferase, O-GlcNAcase: β-N-acetylglucosaminidase, LCFA: 
long-chain fatty acid). 
Fatty acid 
accumulation 
GLUT FA transporter 
LCFA 
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1.4. Aims 
 
1. Transfection - we will transfect rat cardiac-derived H9c2 myoblasts 
with a human ACCβ promoter-luciferase construct and a GFAT 
overexpression construct. The myoblasts will be treated with various 
inhibitors to test whether the HBP regulates the ACCβ promoter. 
 
2. Western blotting (in vitro) – Protein extracted from transfected 
myoblasts will be analysed by Western blotting for the expression of 
GFAT and O-GlcNAc. 
 
3. Western blotting (in vivo) – Proteins will be extracted from cardiac 
tissue from a transgenic mouse model of obesity-induced type-2 
diabetes (db/db mouse) and analysed for altered expression of GFAT 
and O-GlcNAc. 
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2.1. Transfections 
 
2.1.1 Background to principles of the technique 
 
Transfection, i.e. experimental exogenous transfer of DNA into a target cell is 
a useful method to exploit in order to measure gene promoter activity (Figure 
5). Two components are required for a successful transfection. Firstly, a 
transfection reagent is required that will bind to plasmid DNA to be transferred 
into the cytosol of cells. For example, for this study Fugene 6 transfection 
reagent (Roche, Penzberg, Germany) was employed. The second 
requirement is a plasmid DNA that will be transfected together with the 
promoter-luciferase construct. The former is constitutively expressed and 
used to normalise transfection results according to cell number and 
transfection efficiency.   
 
The gene promoter of interest is bound to a firefly luciferase gene, allowing 
promoter activity to be measured by the amount of luciferase protein 
synthesized by the cell. The normalising construct employed for this thesis 
was pRL-CMV (Promega, Fitchburg, WI, USA). The luciferin protein 
expressed by the pRL-CMV construct is isolated from Renilla reniformis. After 
transfection, luciferin protein is extracted by cell lysis. Thereafter a substrate 
called luciferase assay reagent II (LAR II) is added to activate the luciferin 
protein, resulting in light emission. The latter can be measured using a 
luminometer. Since the luciferin protein produced by the normalising agent 
and the promoter construct are different, each can be measured separately 
from the same sample. Thus, a Dual-Luciferase Reporter Assay Kit 
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(Promega, Fitchburg, WI, USA) was used where two substrates were added 
to the same sample, i.e. Luciferase Assay Reagent II (LAR II) (measuring 
promoter activity) and “Stop and Glo” (neutralizes LAR II substrate and 
activates the Renilla luciferin).   
 
 
 
 
+ 
pRL-CMV Promoter of 
interest bound to 
luciferase gene 
Fugene 6 Transfection Reagent 
Fugene 6 binds with plasmid and transports it through lipid bilayer 
pRL-CMV Promoter luciferase 
construct 
Cell membrane 
Cytosol 
Extracellular 
Renilla-luciferin 
protein 
LIGHT 
Figure 5: Outline of principles governing gene promoter activity 
measurements using luciferase assay. 
(light: marker of gene promoter activity, LAR II: Luciferase assay reagent II, pRL-CMV: Renilla-luciferase 
construct).  
Firefly-luciferin 
protein 
+ + 
LAR II 
Reagent 
Stop & Glo 
Reagent 
LIGHT 
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Transfections were performed as a 5-day experiment (Figure 6). On the first 
day cells were seeded on 12-well plates. On day 2 cells were transfected, 
while media of myoblasts was replaced on day 3. This ensured that myoblasts 
were supplied with sufficient nutrients and also to remove excess transfection 
reagent. At this stage inhibitors/drugs that were being tested were added (to 
be discussed later).  On day 4, after 24 hours treatment, cells were lysed and 
the lysate stored at -80°C.  The samples were rapidly thawed on day 5 to 
further enhance cell lysis. Samples were subsequently plated on a 96-well 
luminometer plate and promoter activity measured (Figure 6). 
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Figure 6: Outline of transfection schedule. 
Day 4: Extract cell lysates using Dual-Luciferase Reporter 
Assay Reagent Kit and store -80°C 
Day 2: Performed transfection 
 
Day 3: Change media on cells ± experimental 
manipulation 
Day 1: Seed H9c2 myoblasts in 12-well culture plates 
(seeding density ~35,000 cells/well) 
Day 5: Perform a luciferase assay using Dual-Luciferase 
Assay Reporter Kit and luminometer 
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2.1.2. Cell culture 
 
H9c2 rat cardiac-derived myoblasts were chosen for experiments because 
they are a precursor cell line to cardiomyocytes (19, 38, 91). Precursor cells 
are also easier to differentiate than terminally differentiated myotubes. H9c2 
myoblasts were cultured in T75 culture flasks with Dulbecco’s modified 
Eagle’s medium (DMEM) (Highveld, South Africa) with 10% GibCo foetal calf 
serum (Invitrogen, Carlsbad, CA, USA) and 4 mM GibCo L-glutamine 
(Invitrogen, Carlsbad, CA, USA). Cells were not allowed to grow to a 
confluency greater than 80-90% and were cultured for a maximum of 8 
passages before growing new cells. We used passages 9-15 for transfection 
experiments. In our initial optimizing experiments passages 9-15 were used 
and it was decided to continue using them in order to ensure consistency 
between results.  
 
Myoblasts were grown as described and plated at 35, 000 cells per well on 
12-well culture plates (Greiner, Kremsmünster, Austria) in 1 ml of completed 
DMEM with 10% foetal calf serum and 4 mM L-glutamine. The cells were 
incubated for 24 hours at 5% CO2, 20% O2 and 95 % humidity at 37°C prior to 
transfection.  
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2.1.3. Promoter-luciferase and DNA constructs used for 
transfection experiments 
 
pGL3-Control (Promega, Madison, WI, USA) was used in all transfection 
experiments to normalise results according to cell number and transfection 
efficiency. pGL3-Control is a plasmid constitutively expressing luciferase from 
an SV40 promoter. pGL3-Basic is a plasmid lacking a promoter and therefore 
expresses only baseline levels of luciferase. The latter was used to normalise 
the total amount of DNA used per transfection to ensure comparable 
transfection efficiency between experiments. The total amount of DNA 
transfected for each experiment was 0.75 µg, and pGL3- Basic was used to 
make up the remaining DNA needed. H9c2 myoblasts were transiently 
transfected with a 1,317 bp human ACCβ promoter-luciferase reporter 
construct (pPIIβ-1,317) previously described (Makaula et al., 2006) (75). 0.25 
µg of pPIIβ-1,317 was transfected ± 0.25 µg of a human pcDNA3-GFAT 
expression vector (123). Two dominant negative constructs, i.e. pcDNA3-
GFAT577 and pcDNA3-GFAT667 were also employed in this study (123). 
Both dominant negative constructs were separately transfected with pPIIβ-
1,317 and GFAT. There is a great amount of sequence homology between 
the rat and human isoforms of GFAT (91%) and ACCβ (90%) and therefore it 
is unlikely that this would represent a problem when expressing human 
constructs in a rat cardiac-derived cell line.  
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Description of plasmid constructs: 
 
1. pcDNA3-GFAT (see Figure 7) contains a full-length human GFAT 
cDNA generated by RT-PCR and cloned into the expression vector 
pcDNA3.1 (see Figure 8) (Invitrogen, Inchinnan, Scotland). The PCR 
product was verified by sequencing and shows identity to human GFAT 
(also known as GFAT1 = glutamine:fructose-6-phosphate 
transaminase 1, GenBank accession number M90516). This construct 
was kindly donated to us by Dr. Cora Weigert (University of Tübingen, 
Germany). 
 
 
 
Human GFAT 
BamH1 
EcoR1 
P CMV 
pcDNA3-GFAT 
~7.5 kb ~2.1 kb 
Figure 7: Sketch of human GFAT gene cloned into pcDNA3.1 vector 
(123). (from Weigert et al., 2003) (pRL-CMV: Vector, GFAT: glutamine:fructose-6-phosphate 
amidotransferase, EcoR1 and BamH1 are restriction splice sites). 
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2. pcDNA3-GFAT/577 contains human GFAT1 cloned into the pcDNA3.1 
vector but with histidine 577 mutated to alanine, resulting in the 
complete loss of GFAT enzyme activity (Weigert et al., 2003). 
 
3. pcDNA3-GFAT/677 contains human GFAT1 cloned into the pcDNA3.1 
vector but with lysine 667 mutated to alanine, leading to complete loss 
of GFAT enzyme activity (Weigert et al., 2003). 
 
 
 
 
 
 
 
Figure 8: Diagram of pcDNA3 vector (from brochure supplied by Invitrogen, 
Carlsbad, CA, USA). 
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4. pPIIβ-1,317 is a full-length human ACCβ promoter reporter luciferase 
construct that contains 4 E-boxes (CANNTG) (Figure 9) (Makaula et al, 
2006). 
 
 
 
5. TransLucent USF Reporter Vector (USF-L) contains promoter 
recognition sites for both upstream stimulatory factor 1 (USF1) and 
upstream stimulatory factor 2 (USF2) cloned into a pTransLucent 
Vector (catalog number LROO86, Panomics, Redwood City, USA) 
(Figure 10).  
 
 
 
 
 
 
 
Luciferase 
E3 E2 E1 E4 
pPIIβ-1,317  
ACCβ promoter region = 1,317 bp  
Four ‘’E-boxes’’ identified (E1-E4): important regulatory elements for transcription 
factors such as upstream stimulatory factor (USF) 
Figure 9: Diagram of pPIIβ-1,317 construct (modified from Makaula et al., 2006). 
(E1: Ebox 1, E2: Ebox 2, E3: Ebox 3, E4: Ebox 4, pPIIβ-1317: human ACCβ pomoter-reporter construct). 
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2.1.4. Preparation of plasmid DNA 
 
Each expression vector was amplified in Escherichia coli cultures (JM109 
competent cells, Promega, Madison, WI, USA) and extracted using the 
Qiagen® Plasmid Purification Maxi Kit (Qiagen, Invitrogen, Carlsbad, CA, 
USA). Purified DNA was quantified using a spectrophotometer (wavelengths 
of 260 nm and 280 nm) and its quality checked by restriction enzyme 
analysis. The DNA was electrophoresed on a 1% agarose gel to check for the 
quality of the DNA. 
 
pTransLucent 
4.8 kb 
pUC ori 
Ampr 
F1 ori 
Luciferase 
gene 
USF 
HindIII 
NcoI 
Figure 10: Diagram of pTransLucent construct. (Panomics, Redwood City, USA). 
(HindIII and NcoI are restriction sites where the USF promoter is cloned). 
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2.1.5. Transfection procedures 
 
On Day 2 of transfection experiments the cells were transfected with the DNA 
of interest (Figure 6). Transfections were performed in triplicate for each 
experiment and repeated to generate the necessary numbers for statistical 
analysis. First, a stock solution of pGL3-Control DNA (pRL-CMV) was made in 
media concentration of 10 ng/ml (see step 1 of Figure 11). The media 
contained DMEM and 4 mM L-glutamine. The stock solution was aliquoted 
into separate microfuge tubes to a final volume of 165 µl for every transfection 
experiment (consisting of three replicates for each experiment) (see step 2 of 
Figure 11). DNA was aliquoted into its respective microfuge tubes with pGL3-
Basic making up the total DNA mass to 0.75 µg (step 3 of Figure 11).  
 
A second stock solution was then prepared with an equal volume of media 
containing Fugene 6 Transfection Reagent (Roche, Penzberg, Germany). 
Here, a 2:1 ratio of Fugene 6: DNA (with DMEM and 4 mM L-glutamine) was 
used. 165 µl of the Fugene 6 solution was then added to each of the 
microfuge tubes containing DNA and incubated at room temperature for 15 
minutes (steps 4, 5 of Figure 11).  
 
Meanwhile, 0.9 ml of fresh medium (containing DMEM, 10% FCS and 4 mM 
L-glutamine) was added to the H9c2 cells before the transfection. The final 
volume of the DNA/Fugene 6 cocktail therefore equalled 330 µl in each 
microfuge tube for each transfection experiment.  
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DMEM + 4 mM L-glutamine 
10 ng PRL-CMV 
+ 
Aliquot 165 µl in each 1.5 ml microfuge tubes 
1 2 3 4 5 
Aliquot DNA into tubes up to a total of 0.75 
µg DNA 
Example: 
Tube 1: 
Tube 2: 
= 
= 
0.75 µg of pGL3-Basic 
0.25 µg pPIIβ-1317 + 0.5 µg pGL3-Basic 
Step 1: 
Step 2: 
Step 3: 
DMEM + 4 mM L-glutamine 
1.5 µ l Fugene 6 transfection reagent (n = 3) 
+ 
Aliquot 165 µl in each 1.5 ml microfuge tube 
with DNA 
1 2 3 4 5 
Incubate for 15 minutes at room temperature 
12-well culture plate 
Aliquot 100 µ l DNA:Fugene cocktail into each of three wells representing a triplicate 
Example: 
Tube 1: 
1 2 3 4 
= 
(Fugene:DNA = 2:1) 
Step 4: 
Step 5: 
Step 6: 
Figure 11: Outline of day 2 transfection procedure.  
(n: number of samples, DMEM: Dulbecco’s modified Eagle’s medium, pGL3-Basic : vector, PRL-CMV: Renilla luciferase 
construct). 
Stellenbosch University  http://scholar.sun.ac.za
 37 
The DNA/Fugene 6 solution was added to the H9c2 myoblasts (100 µl per 
well to make a final volume of 1 ml per well). The solutions were applied in 
triplicate (step 6 of Figure 11). The plates were gently rocked and then 
incubated at 37°C for 24 hours. 
 
 After 24 hours the media on the cells was changed. During this media 
change various drugs of interest were added to cells. We employed the 
following agents: 0.1 mM, 1 mM and 2 mM alloxan (Sigma-Aldrich, St. Louis, 
Missouri), 40 µM and 80 µM azaserine (Sigma-Aldrich, St. Louis, Missouri), 
40 µM and 80 µM 6-Diazo-5-oxo-L-norleucine (DON) (Sigma-Aldrich, St. 
Louis, Missouri) and 5 mM and 10 mM streptozotocin (STZ) (Sigma-Aldrich, 
St. Louis, Missouri). Twenty-four hours later cells were lysed, protein 
extracted and expression of luciferase measured using the Glomax 
luminometer (Promega, Fitchburg, WI, USA). 
 
The protocol and reagents used were as stipulated in the manual of the Dual-
Luciferase Reporter Assay Kit (Promega, Fitchburg, WI, USA). First the cells 
were washed with phosphate buffer saline and then 200 µl of Passive Lysis 
Buffer (Promega, Fitchburg, WI, USA) was added to each well. The 12-well 
plate was then incubated on a shaker at room temperature for 15 minutes. 
The lysis buffer and cells from each well were transferred to microfuge tubes. 
A separate microfuge tube was used for each well of the 12-well plate. The 
microfuge tubes carrying the cells and lysis buffer were stored at -80°C 
(Figure 12). On Day 5 the lysate was thawed in water and vortexed. The 
microfuge tubes were centrifuged at 12,000 rpm at 4°C for 2 minutes with a 
ALC multispeed refrigerated centrifuge PK 121R (Intergrated Services, New 
Stellenbosch University  http://scholar.sun.ac.za
 38 
Jersey, USA). 10 µl of each sample was aliquoted into a separate well on a 
96-well luminometer plate (Amersham, Buckinghamshire, UK).  
 
 
 
 
 
 
 
 
 
Remove media and wash of cells with phosphate buffer saline 
Leave plate on a shaker for 15 minutes at room temperature 
Extract lysates and place each into separate microfuge tubes and 
store at -80°C 
Add 200 µl of Passive Lysis Buffer from Dual-Luciferase Reporter Assay Kit in 
each well of 12-well culture plate 
Example: 
1 2 3 4 
Store at -80°C 
Step 1: 
Step 2: 
Step 3: 
Step 4: 
Figure 12: Outline of day 4 lysate extraction. 
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Two reagents had to be prepared. Reagent 1 contained Luciferase Assay 
Reagent II (LAR II) and reagent 2 Stop and Glo reagent (Figure 13). Both 
reagents were provided with the Dual-Luciferase Reporter Assay Kit 
(Promega, Fitchburg, WI, USA). The luminometer plate, together with the two 
reagents, was placed in the luminometer. The luminometer was set up to add 
50 µl of LAR II, delay for 2 seconds and then take a reading for 8 seconds. 
This gave a measurement for human ACCβ promoter (pPIIβ-1,317) activity. 
The luminometer then added “Stop and Glo” to the same well and delayed for 
2 seconds before measuring the light released (for another 8 seconds). This 
yielded the measurement for the Renilla construct (pRL-CMV) of the same 
sample. The process was repeated for each well, providing two readings for 
each sample (Figure 13). 
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Figure 13: Performing the luciferase assay on day 5. 
Thaw samples in a waterbath at room temperature 
Vortex samples and then centrifuge at 12,000 rpm at 4°C for 2 minutes 
Aliquot 10 µl of each sample onto a 96-well luminometer plate 
Place in luminometer with reagent 1 and reagent 2 
Samples from Day 4 Step 1: 
Step 2: 
Step 3: 
Step 4: 
Step 5: 
For each sample the luminometer will add 50 µl of reagent 1, 
take a reading, add 50 µl reagent 2 and then take a second 
reading. 
Reagent 1: Luciferase Assay 
Reagent (measures activity 
of firefly luciferase gene, i.e. 
promoter of interest) 
Reagent 2: Stop and Glo Reagent 
(measures activity of Renilla luciferase 
gene, i.e. pRL-CMV which is the 
normalising control) 
Normalize for transfection efficiency 
and against the vector and perform 
statistical analysis 
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2.1.6. Statistical analyses of transfection results 
 
Luminometer firefly readings for each experiment were normalised against its 
respective Renilla luminometer reading by dividing the firefly reading by its 
renilla reading. Each experiment was performed in triplicate each time a 
transfection was carried out. Each replicate of an experiment was added 
together and then divided by 3 to give a mean value for each experiment. This 
provided a mean value for each experiment that was normalised according to 
transfection efficiency and cell number. To eliminate any vector effects (i.e. in 
which the construct were cloned) on the experiment, each of the mean values 
were divided by the vector’s mean value. 
 
The transfection experiments were repeated numerous times to provide a 
larger number of replicates for each experiment. Measurements from all the 
same experiments were combined and Graphpad Instat version 3.01 
(GraphPad Software Inc., San Diego CA) used to perform statistical analyses 
of these values. First the mean and standard error of the mean and standard 
deviation was calculated. A 95% confidence interval was also calculated. 
Replicates of an experiment that were outside the 95% confidence interval or 
were not within two standard errors of the mean were discarded. The 
remaining replicates were used to plot a graph. Student-Newman statistical 
test was used to see if there were in significant differences between controls 
and the experiments in each set of experiments. Values p< 0.05 were taken 
as being significant. 
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2.2. Protein and RNA extraction from transfected cells 
 
On day 4 of transfection experiments, protein and RNA were extracted from 
H9c2 myoblasts using an Allprep RNA/Protein extraction kit (Qiagen, 
Invitrogen, Carlsbad, CA, USA). This was done in duplicate so that a 
luciferase assay could be performed to confirm that transfection experiments 
were indeed successful. Protein extracted from these cells was used in 
Western blotting experiments, while the RNA was stored for future real-time 
PCR experiments. 
 
2.3. Western blotting 
 
2.3.1. Sample preparation and quantification of protein from 
cells 
 
The protein extracted using the Allprep RNA/Protein extraction Kit was 
quantified using the Qubit flourometer (Invitrogen, Carlsbad, CA, USA).  
Protein was prepared with an equal volume of sample buffer and boiled for 5 
minutes, centrifuged at 14,000 rpm for 5 seconds before loading onto a SDS-
polyacrylamide gel for electrophoresis.  
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2.3.2. Tissue biopsies acquired from db/db transgenic mouse 
model of type-2 diabetes 
 
Previously collected heart tissues from 20-week-old male and female db/db 
mouse and matching controls (db/+) were used. This mouse has a point 
mutation in the leptin receptor gene and gains weight with age (15). They also 
develop insulin resistance and hyperglycaemia, eventually progressing to 
type-2 diabetes. The symptoms of type 2 diabetes are similar to that observed 
in the human condition making this a good model to explore my hypothesis in 
an in vivo setting. We used heterozygous (db/+) instead of homozygous (+/+) 
as controls because of a lack of animal supply.   
 
2.3.3. Sample preparation and quantification of protein from 
heart tissues 
 
Protein was extracted from male and female db/db mouse and heterozygous 
mouse heart muscle tissue biopsies and stored in RIPA buffer (refer to 
Appendix 1 for extraction method).  Total protein was quantified using the 
Bradford method for protein determination (see Appendix 2 for Bradford 
method). 50 µg of sample was then added to an equal volume of sample 
buffer and boiled for 5 minutes. The samples were then electrophoresed on a 
SDS-polyacrylamide gel. 
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2.3.4. Gel analysis 
 
Protein extracts were electrophoresed on a 10% SDS-polyacrylamide gel with 
a 4% stacking gel at 200 V for 1 hour. 10 µl of a protein marker (BioRAD 
precision Plus protein standard cat. # 161-0374, Bio-RAD Laboratories, 
California, USA) was used in lane 1 of gels. The amount of protein loaded per 
well was 50 µg for each sample. The protein was then transferred to a PVDF 
membrane using a semi-dry transfer apparatus (Bio-RAD Laboratories, 
California, USA) for 1 hour (See Appendix 3 for electrotransfer procedure).   
 
The membranes were used to probe for three proteins of interest:  
1) O-GlcNAc was detected using an O-GlcNAc Western Blot Detection Kit 
(Pierce, catalogue number 24565, Rockford, Illinois) (Refer to Appendix 4 for 
complete protocol).  
 
2) GFAT (Refer to Appendix 5 for the complete protocol). The GFAT antibody 
was kindly donated by Dr. Cora Weigert (University of Tübingen, Germany).  
 
3) β-actin (Cell Signaling, Danvers, MA, USA) was also employed to check for 
equal protein loading (Refer to Appendix 6 for protocol). 
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2.3.5. Analysis of Western blot results 
 
Results from western blots were analysed by densitometry. For the in vivo 
studies db/db protein extracts were probed with O-GlcNAc or GFAT antibody, 
reprobed with β-actin (Cell Signaling, Danvers, MA, USA) and then 
densitometry was performed. The densitometry was performed by scanning 
the blots with an HP Scanjet 3500c scanner (Hewlett Packard, Palo Alto CA) 
and densitometry was performed on the scanned pictures using Un-Scan-It 
Gel version 5.1 (Silk Software, Orem, UT). The densitometry value for a 
sample was normalised against its β-actin densitometry value. Then all the 
normalised densitometry values from db/db were pooled together (likewise for 
db/+). The combined protein expression for db/+ was compared to that of 
db/db using appropriate statistical analyses to evaluate if there was a 
significant change in protein expression. 
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3.1. Transfections 
 
Before investigating our hypothesis, my initial experiments were focused on 
optimising the transfection procedure for H9c2 myoblasts. Here myoblasts 
were transfected with different concentrations of the ACCβ promoter-
luciferase reporter construct (pPIIβ-1317/+65) ± different concentrations of 
GFAT expression vector ± different concentrations of dominant negative 
GFAT/577 or GFAT/677 constructs. After considerable effort, I eventually was 
in a position to select optimal DNA concentrations for use in transfection 
experiments (Figure 14). For these initial experiments a total of 1 µg of DNA 
per experiment was employed. The results obtained showed inconsistency. 
The transfection procedure was then re-optimised. Thus, for the experiments 
which followed we used 0.75 µg of DNA per experiment; however the Fugene 
6 to DNA ratio remained at 2:1. 
 
 ## 
Figure 14: Results of pilot co-transfection experiments performed with ACCβ promoter, 
GFAT and dominant negative constructs (GFAT/577 and GFAT/667). 
(∗ p<0.001 vs. ACCβ [n=9], ∗∗ p<0.05 vs. ACCβ [n=9], ∗∗∗ p<0.01 vs. ACCβ [n=9], # p<0.01 vs. ACCβ [n=9], ## p<0.001 vs. 
ACCβ+ 0.4 µg GFAT [n=5]. Vector: pRL-CMV, ACCβ: pPIIβ-1317/+65, GFAT: glutamine:fructose-6-phosphate amidotransferase). 
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After establishing and optimising the transfection procedure I next proceeded 
to investigate my hypothesis. To ensure that results were statistically relevant 
experiments were repeated several times (at least an n=6).  
 
I began by transiently transfecting H9c2 myoblasts with the human ACCβ 
promoter-luciferase reporter construct (pPIIβ-1317/+65) ± a GFAT expression 
vector ± dominant negative GFAT/577 or GFAT/677 constructs. The results 
showed that GFAT overexpression induced ACCβ gene promoter activity by 
75 ± 23% (p<0.001, n=6). Co-transfection with either GFAT/577 or GFAT/667 
constructs resulted in marked attenuation of this induction (Figure 15). 
 
 
 
 
 
 
Figure 15: GFAT overexpression induces ACCβ gene promoter activity.  
(∗ p<0.001 vs. ACCβ [n=9], ∗∗ p<0.001 vs. ACCβ+GFAT [n=6], # p<0.001 vs. ACCβ+GFAT [n=6]. Vector: pRL-CMV, 
ACCβ: pPIIβ-1317/+65, GFAT: glutamine:fructose-6-phosphate amidotransferase). 
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To assess the extent of GFAT regulation on ACCβ gene promoter activation, 
H9c2 myoblasts were treated with varying doses of L-glutamine (0 mM, 4 mM 
and 8 mM) a substrate for the hexosamine biosynthetic pathway (HBP). Here, 
glutamine induced ACCβ promoter activity in a dose-dependent manner 
(Figure 16). There was no significant change in ACCβ promoter activity in the 
absence of GFAT (Figure 16). 
 
 
 
 
 
 
 
 
 
Figure 16: Glutamine induces ACCβ promoter activity in a dose-dependent manner.  
(∗ p<0.05 vs. ACCβ + GFAT 0 mM L-Glutamine [n=7], ∗∗ p<0.01 vs. ACCβ+GFAT + 0 mM L-Glutamine [n=7]. Vector: 
pRL-CMV, ACCβ: pPIIβ-1317/+65, GFAT: glutamine:fructose-6-phosphate amidotransferase). 
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Since GFAT-induced ACCβ promoter activity was inhibited by dominant 
negative constructs, I next performed additional comfirmatory experiments by 
pharmacological inhibition of GFAT. Two inhibitors of GFAT were used, i.e. 6-
Diazo-5-oxo-L-norleucine (DON) and azaserine (Figure 17). 
 
 
 
 
 
 
 
 
 
Glucose 
GFAT 
Glc-6-P F-6-P GlcN-6-P UDP-GlcNAc 
OGT O-GlcNAcase 
O-GlcNAc modification  
of nuclear proteins 
Glutamine 
DON 
Azaserine STZ 
Alloxan 
Figure 17: Description of inhibitors of HBP and where they operate. 
Glc-6-P: glucose-6-phosphate, F-6-P: fructose-6-phospahate, GlcN-6-P: N-glucosamine-6-phosphate, 
UDP-GlcNAc: uridine diphospho-N-acetylglucosamine, OGT: O-linked β-N-acetylglucosamine transferase, 
GFAT: glutamine:fructose-6-phosphate amidotransferase, O-GlcNAc: O-linked N-acetylglucosamine 
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Two concentrations of DON were used (40 µM and 80 µM) to determine the 
effectiveness of DON inhibition (Figure 18). It was suggested in the literature 
that 40 µM of DON would be a physiologically relevant dose to achieve the 
required effect. Since the cell line used in this study was different to published 
data the dose was also doubled to 80 µM in case the 40 µM dose failed to 
inhibit GFAT. 
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Figure 18: Results of co-transfection experiments performed with ACCβ, GFAT and 
different concentrations of inhibitors of HBP. 
(∗ p<0.05 vs. ACCβ [n=9], ∗∗ p<0.05 vs. ACCβ+GFAT [n=10], ∗∗∗ p<0.01 vs. ACCβ+GFAT [n=9], # p<0.01 vs. ACCβ+GFAT+STZ 
[n=7]. Vector: pRL-CMV, ACCβ: pPIIβ-1317/+65, GFAT: glutamine:fructose-6-phosphate amidotransferase, DON: 6-Diazo-5-oxo-
L-norleucine, STZ: Streptozotocin). 
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Since both the 40 µM and 80 µM concentrations worked equally well (Figure 
19) we continued by using the 40 µM dose as it was more cost effective.  
 
 
 
 
 
Two concentrations of azaserine were tested (40 µM and 80 µM) (Figure 19). 
Again, as before we employed the 40 µM dose because of cost effectiveness. 
Azaserine markedly blunted GFAT-induced ACCβ promoter activity (Figure 
20). Therefore both the dominant negative and pharmaceutical data 
substantially strengthen our hypothesis that the HBP regulates ACCβ 
promoter activity. 
 
Figure 19: Pharmacological inhibition of GFAT abolishes ACCβ promoter induction.  
 (∗ p<0.001 vs. ACCβ [n=35], ∗∗ p<0.001 vs. ACCβ+GFAT [n=25]. Vector: pRL-CMV, ACCβ: pPIIβ-1317/+65,  
GFAT: glutamine:fructose-6-phosphate amidotransferase, DON: 6-Diazo-5-oxo-L-norleucine). 
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Additional pharmaceutical agents were next employed to further examine the 
regulation of ACCβ promoter activity by downstream targets of the HBP. Here 
H9c2 myoblasts were treated with various concentrations of alloxan (0.1 mM, 
1 mM and 2 mM), an inhibitor of O-linked β-N-acetylglucosaminyl transferase 
(OGT) (Figure 17). The results show that increasing concentrations of alloxan 
result in a corresponding decrease of ACCβ promoter activity in response to 
GFAT overexpression (Figure 21). Moreover, at the 2 mM alloxan 
concentration there was a significant reduction in ACCβ promoter activity 
(Figure 21).  
 
 
 
 
 
 
Figure 20: Pharmacological inhibition of GFAT attenuates ACCβ promoter induction. 
(∗ p<0.001 vs. ACCβ [n=35], ∗∗ p<0.001 vs. ACCβ+GFAT [n=24]. Vector: pRL-CMV, ACCβ: pPIIβ-1317/+65,  
GFAT: glutamine:fructose-6-phosphate amidotransferase). 
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A second pharmacologic inhibitor, i.e. streptozotocin (STZ), an inhibitor of β-
N-acetylglucosaminidase (O-GlcNAcase) was used to investigate downstream 
targets of the HBP on the regulation of ACCβ promoter activity (Figure 17). 
Thus I expected to observe an increase in ACCβ promoter activity in this 
instance. Two concentrations of STZ were used (5 mM and 10 mM) in 
preliminary testing, and we thereafter employed the 5 mM dose (Figure 19). 
Interestingly, these results show that STZ further enhanced GFAT-induced 
ACCβ promoter activity (Figure 22). 
 
 
 
 
Figure 21: Pharmacological inhibition of OGT blunts ACCβ promoter induction. 
(∗ p<0.001 vs. ACCβ [n=35], ∗∗ p<0.001 vs. ACCβ+GFAT [n=16]. Vector: pRL-CMV, ACCβ: pPIIβ-1317/+65, 
GFAT: glutamine:fructose-6-phosphate amidotransferase). 
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These data therefore show that the human ACCβ gene promoter is regulated 
by these two downstream HBP regulators, i.e. OGT and O-GlcNAcase. To 
further strengthen these findings I next performed experiments using both an 
inhibitor of GFAT (i.e. DON) and an inhibitor of O-GlcNAcase (i.e. STZ) 
(Figure 17). In agreement with our earlier findings, DON attenuated STZ-
mediated upregulation of ACCβ promoter activity (Figure 23).  
 
Figure 22: Pharmacological inhibition of O-GlcNAcase further increases ACCβ 
promoter activity.  
(∗ p<0.001 vs. ACCβ [n=35], ∗∗ p<0.001 vs. ACCβ+GFAT [n=12]. Vector: pRL-CMV, ACCβ: pPIIβ-1317/+65, 
GFAT: glutamine:fructose-6-phosphate amidotransferase, STZ: Streptozotocin). 
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To gain further insight into transcriptional mechanisms underlying GFAT-
mediated induction of ACCβ promoter activity, we employed a candidate 
transcription factor approach. Since our laboratory previously implicated 
upstream stimulatory factors (USFs) in ACCβ promoter regulation (Makaula et 
al., 2006) I next tested USF1 and USF2 as transcriptional regulators in the 
GFAT-mediated induction of ACCβ gene promoter. Here, USF2 induced 
ACCβ promoter activity by 44 ± 23% (p<0.001, n=6). However, when co-
transfected with GFAT, USF2 did not further increase ACCβ promoter activity 
(Figure 24).  
 
 
+40 µM DON 
+5 mM STZ 
+40 µM DON + 5 mM STZ 
 ∗∗∗ 
7 
6 
5 
4 
3 
2 
1 
0 
Vector ACCβ 
ACCβ+GFAT 
 ∗ 
∗∗ 
# 
Fo
ld
 
in
du
ct
io
n
 
Figure 23: Pharmacological inhibition of inhibition of GFAT together with 
inhibition of O-GlcNAcase attenuates ACCβ promoter induction.  
(∗ p<0.001 vs. ACCβ [n=33], ∗∗ p<0.001 vs. ACCβ+GFAT [n=10],∗∗∗ p<0.001 vs. ACCβ+GFAT [n=12], # p<0.05 
vs. ACCβ+GFAT [n=7], # p<0.001 vs. ACCβ+GFAT+STZ [n=7]. Vector: pRL-CMV, ACCβ: pPIIβ-1317/+65, 
GFAT: glutamine:fructose-6-phosphate amidotransferase). 
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We further tested USF-mediated regulation of the ACCβ promoter by co-
transfecting a GFAT expression construct together with a USF luciferase 
reporter construct (USF-L = Upstream Stimulatory Factor TransLucent 
Reporter Vector) that contains multiple promoter binding sites for USFs. Here, 
we found a marked induction of the USF-L reporter construct by 80 ± 12% 
(p<0.001, n=5) compared to the vector (Figure 25).  
Figure 24: USF2 overexpression induces ACCβ promoter activity. 
 (∗ p<0.001 vs. ACCβ [n=6], ∗∗ p<0.001 vs. ACCβ [n=6]. Vector: pRL-CMV, ACCβ: pPIIβ-1317/+65, GFAT: 
glutamine:fructose-6-phosphate amidotransferase, USF1: upstream stimulatory factor 1, USF2: upstream  stimulatory 
factor 2.  
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Figure 25: GFAT overexpression enhances USF transcriptional activation.  
(∗ p<0.001 vs. GFAT [n=5]. Vector: pRL-CMV, ACCβ: pPIIβ-1317/+65, GFAT: glutamine:fructose-6-phosphate 
amidotransferase, USF-L: upstream stimulatory factor TransLucent™ Reporter Vector). 
+USF-L  
7 
6 
5 
4 
3 
2 
1 
0 
Vector 
GFAT 
 ∗ 
Fo
ld
 
in
du
ct
io
n
 
Stellenbosch University  http://scholar.sun.ac.za
 58 
3.2. Western blotting 
 
3.2.1. In vitro experiments 
 
To assess the degree of O-GlcNAcation after transfection, we performed 
Western blotting using our well-established protocol. We employed an Allprep 
RNA/Protein extraction Kit (Qiagen, Invitrogen, Carlsbad, CA, USA) to 
simultaneously isolate and purify RNA and protein. Protein extracts were 
probed using an O-GlcNAc Western blot Detection Kit (Pierce, catalogue 
number 24565, Rockford, Illinois). The membrane was stripped and reprobed 
with β-actin antibody. Our preliminary results suggest little difference in the 
level of O-GlcNAc modified proteins when transfected with ACCβ ± GFAT 
(n=3). However, there is a decreasing trend when cells were treated with 40 
µM DON (Figure 26). Additional samples need to be tested to further assess 
this. 
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Figure 26: Degree of O-GlcNAcation after GFAT transfection into H9c2. 
(The densitometry readings were normalised for protein loading using β-actin. Vector: pRL-CMV [n=1], ACCβ: pPIIβ-
1317/+65 [n=3], GFAT: glutamine:fructose-6-phosphate amidotransferase [n=3], DON: 6-Diazo-5-oxo-L-norleucine [n=3]).  
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3.2.2. In vivo experiments 
 
We investigated our hypothesis in a mouse model of type 2 diabetes. Total 
protein was purified from previously collected heart tissue from heterozygous 
(db/+) and homozygous (db/db) female mice and probed for degree of O-
GlcNAcation. Due to animal limitations, we could only test 3 female db/db and 
3 matched db/+ controls. Our preliminary blotting data suggest that O-GlcNAc 
modification of proteins are decreased in the female db/db mouse (Figure 27).  
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Figure 27: Degree of O-GlcNAcation in db/db female mouse heart.  
(The densitometry readings were normalised for protein load using β-actin. ∗ p<0.0008  vs. female db/+ [n=3]). 
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To test whether alterations in O-GlcNAc modification are due to a change in 
GFAT expression, we also assessed GFAT peptide levels in db/db versus 
db/+ female mouse hearts. Our preliminary results suggest a decreasing trend 
in GFAT protein expression (Figure 28). However, additional sample numbers 
are required to confirm whether these trends are indeed true. 
 
 
 
 
 
 
Figure 28: GFAT peptide levels in female diabetic mouse hearts.  
(The densitometry readings were normalised for protein load using β-actin).  
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To elucidate whether these observations were gender dependent, we also 
analysed male db/+ and db/db mouse heart tissue using the GFAT antibody 
(due to time constraints we could not perform O-GlcNAc analysis for male 
heart tissues).  Again, we were limited by sample numbers (n=3 for male 
db/db and db/+). Our early results suggest no differences in GFAT expression 
between male db/+ and db/db mice (Figure 29). However, further studies are 
needed to confirm our preliminary data and whether gender-dependent 
differences do indeed exist.  
 
 
 
Figure 29: GFAT peptide levels in male diabetic mouse hearts.  
(The densitometry readings were normalised for protein load using β-actin [n=3]). 
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Discussion 
 
For this study we tested the hypothesis that increased flux through the 
hexosamine biosynthetic pathway (HBP) induces cardiac ACCβ gene 
expression. A secondary hypothesis resulting from this is that HBP-mediated 
induction would reduce mitochondrial fatty acid uptake/oxidation and result in 
an accumulation of intracellular lipid in the insulin resistant setting 
(hyperlipidaemia). This lipid accumulation will trigger signaling pathways 
resulting in cell death, insulin resistance and contractile dysfunction. The 
secondary hypothesis now forms part of my ongoing studies. The major novel 
finding of this study is that the human ACCβ gene promoter is inducible by 
increased flux via the HBP. Moreover we find that upstream stimulatory 
factors play a crucial role in transcriptional regulation of this process. 
 
Increased flux through the hexosamine biosynthetic pathway has been linked 
to an increase in glucose and glucosamine availability. An increase in HBP 
flux results in higher UDP-GlcNAc production and a general increase in O-
GlcNAc modification of a large number of proteins and transcription factors. 
O-GlcNAc has been shown to operate in opposition to phosphorylation, 
glycosylating proteins that are dephosphorylated and vice versa (21, 59, 65). 
Studies have proposed that the hexosamine biosynthetic pathway functions 
as a cellular nutrient sensor and numerous papers have showed a correlation 
between increased flux through the HBP and insulin resistance (10-12, 41, 79, 
96). For example, Marshall et al. (1991) first proposed a role for glucose flux 
via the HBP in insulin resistance from a series of experiments performed in 
isolated rat adipocytes (77). Other studies found a correlation between the 
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HBP and insulin resistance in rodents treated with glucose/glucosamine (18, 
22, 25, 51). Recently, increased O-GlcNAc modification has been attributed to 
altered glucose uptake resulting in insulin resistance (79, 80, 96, 132). A 
study investigating overexpression of OGT in adipose and muscle of mice 
resulting in increased O-GlcNAcation showed insulin resistance and 
hyperleptinaemia (81, 132). These studies would suggest that increased HBP 
flux and increased O-GlcNAcation can impact on fatty acid and glucose 
pathways. In this study we tried to confirm this in vivo by investigating GFAT 
expression and O-GlcNAc modification in the mouse heart. Although, we were 
able to see some differences in our results, the sample size was too small to 
draw any meaningful conclusions. 
 
Several experiments completed for this study supports our primary 
hypothesis.  
 
1. We found that GFAT overexpression increased ACCβ promoter activity by 
~75% in cardiac myoblasts. This would suggest that increased HBP flux 
results in O-GlcNAc modification of transcriptional targets thereby inducing 
ACCβ promoter activity.  
 
2. ACCβ gene promoter activity was induced in a dose-responsive manner to 
increasing glutamine concentrations (glutamine being an HBP substrate).  
 
 
It is important to note that the media used in culturing cells utilises 4 mM L-
glutamine for standard growing conditions. Cells that were cultured at 0 mM L-
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glutamine grew slower than those at 4 mM and 8 mM L-glutamine. We 
therefore had to ensure that the L-glutamine concentration of our growing 
media maintained the same concentration for all experiments to ensure that 
results were reproducible. We are considering using varying doses of 
glucosamine (another substrate for the HBP) in future experiments.  
 
3. Cotransfection of myoblasts with two dominant negative constructs 
(competitive inhibitors of GFAT) attenuated dGFAT-mediated ACCβ promoter 
induction.  
 
4. Two specific pharmaceutical inhibitors of GFAT, i.e. azaserine and 6-Diazo-
5-oxo-L-norleucine attenuated GFAT-induced upregulation of ACCβ. 
 
5. To determine whether downsteam regulators were induced in this process 
we employed appropriate pharmaceutical inhibitors of the HBP.  
 
The first downstream target of the HBP we chose to investigate was OGT, an 
enzyme that converts UDP-GlcNAc to O-GlcNAc and then binds it to serine 
and threonine residues of proteins, lipids and transcription factors (12, 64, 71). 
Alloxan (OGT inhibitor) administration reduced GFAT-induced ACCβ promoter 
activity. Of note, O-GlcNAcation is a very important regulatory step in 
developmental processes (42). Previous studies found that complete inhibition 
of OGT is lethal (42, 43, 86, 104). However for these experiments performed 
no obvious signs of large scale cell death were observed on examination 
under the light microscope at 10, 000 X magnification. I propose that this 
could be because the concentration we used was low (0.1 mM - 2 mM) and 
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probably did not completely inhibit OGT activity. Another possibility may be 
that we were investigating the HBP in rat cardiac-derived myoblasts, and 
hence the aforementioned concern would only be applicable to tissue and 
whole organ development. 
 
We also tested a pharmaceutical inhibitor of O-GlcNAcase, i.e. streptozotocin 
(132). Here we found that streptozotocin treatment enhanced ACCβ promoter 
activity. Of note, streptozotocin is an inhibitor that is widely used to investigate 
type 1 diabetes (95), known to destroy pancreatic β-cells (93). However, in 
our model we did not observe any cell death. This was confirmed by visually 
comparing cell viability between wells that contained seeded cells treated ± 
streptozotocin between media changes on day 3 and day 4 of the transfection 
procedure (Figure 2 of Methods section). I propose that this is probably due to 
the cell type (H9c2 myoblasts) used in this study. It has also been shown that 
an increase in O-GlcNAcation is linked to insulin resistance (5, 14, 42, 81, 90, 
120). This would explain why streptozotocin is lethal to pancreatic β-cells and 
why it is so effective in creating a type 1 diabetic model, i.e. the type 1 
diabetes is created by destroying the insulin-producing cells after they fail to 
maintain β-cell compensation (16, 93). Cardiomyocytes and H9c2 myoblasts 
(precursor cells to cardiomyocytes) do not produce insulin or function as β-
cells and thus would not be affected in this way. 
 
To further strengthen our hypothesis we combined DON and streptozotocin 
since these inhibitors have opposite effects on the HBP. We found that DON 
decreased ACCβ promoter activity while streptozotocin increased it. Since 
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DON acts higher up in the HBP pathway DON inhibition probably outweighed 
streptozotocin inhibition, resulting in a decreased ACCβ promoter activity.  
 
The data from transfection experiments strongly supported the hypothesis that 
increased flux via the HBP induces ACCβ promoter activity. However, 
increased HBP flux effects are expected to be mediated via O-GlcNAcated 
transcriptional regulation. It is likely that a number/cluster of transcription 
factors form a complex with each other to regulate the ACCβ promoter in 
response to high HBP flux. In light of this we followed a candidate 
transcription factor approach. Here we focused on upstream stimulatory 
factors since it was previously shown to upregulate the ACCβ gene promoter 
(75). Promoter studies in cardiomyocytes have suggested that USF1 can 
mediate ACCβ promoter activity in a glucose-dependent manner, but 
implicates the pentose phosphate pathway (75). USF1 has also been shown 
to induce TGF-β, which has been shown to be upregulated by the HBP (124). 
 
These experiments were performed toward the end of my thesis and thus the 
results are of a preliminary nature. However, my data revealed that USF2, 
and not USF1, regulates ACCβ promoter activity via the HBP. When the 
ACCβ promoter was cotransfected with GFAT together with USF2, this did not 
show a further increase versus USF2 alone. This could be because a “ceiling 
level” of overexpression of the USF2 construct was reached.  
We also cotransfected GFAT with a USF reporter-promoter construct (USF-L) 
containing consensus binding sites for USFs. Interestingly, the USF-L 
construct was induced to a much greater extent then with USF2 alone. These 
data therefore suggest that USF1-USF2 heterodimers may induce ACCβ to a 
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greater extent. In agreement, other studies have shown that USF1 and USF2 
can form either homo- or heterodimers (107, 119).  
 
USF1 has also been associated with the metabolic syndrome and type 2-
diabetes (83). Due to time constraints I could not perform a conventional 
transfection with USF1 and USF2 together. Unfortunately, due to a limitation 
of animal numbers and time constraints our Western blotting results can only 
be considered as preliminary. Preliminary results of Western blotting showed 
that O-GlcNAcation was increased when the cells were cotransfected with 
GFAT and ACCβ reporter-promoter construct but that O-GlcNAcation 
decreased when the myoblasts were treated with DON.  In our preliminary 
mouse studies we saw a reduction of GFAT protein in the female db/db from 
control (db/+) but saw no significant difference in the male mice. We also 
found a decrease in O-GlcNAcation of proteins in female db/db from control 
(db/+). Further experiments will have to be carried out before any 
assumptions can be made as to the relevance of this data. Although, we can 
speculate that an inability of the male diabetic heart to reduce CPT1 inhibition 
could explain why female hearts show a relatively higher degree of protection 
compared to male hearts (30, 56, 116). Should this be found to be the case, 
we may assume that hormones such as estrogen or testosterone may be 
involved in the regulation of the HBP. 
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Conclusion 
 
Our data reveal a novel finding, i.e. that increased flux through the 
hexosamine biosynthetic pathway activates USFs thereby inducing ACCβ 
gene promoter activity in cardiac-derived myoblasts (Figure 30). To date no 
data, as far as I am aware, has been published in this regard. Further studies 
are underway to test our secondary hypothesis, i.e. that HBP-induced ACCβ 
induction reduces fatty acid oxidation, thereby leading to intracellular lipid 
accumulation due to a mismatch between sarcolemmal FA uptake and 
mitochondrial FA oxidation in the insulin resistant setting (Figure 30).  
Subsequently, we propose that intramyocardial lipid accumulation triggers 
signaling pathways resulting in cell death, insulin resistance and contractile 
dysfunction. 
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Figure 30: Schematic diagram of completed studies and planned future investigations. 
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Limitations 
 
A limitation of the transfection technique is the time it takes to optimise the 
transfection protocol. This limited the initial progress of this project.  
 
The effectiveness of an inhibitor of any pathway is determined by its 
specificity for its target. The inhibitors we employed for our experiments are 
well documented in the literature (17, 132). We tried to use as many inhibitors 
for the same target site as we could to strengthen our results. However, we 
are aware these inhibitors could also inhibit/enhance other intracellular 
signaling pathways. However, we also employed two dominant negative 
GFAT constructs which considerably strengthened our data. 
 
Due to time constraints and limitation on animal numbers we were unable to 
investigate the differences in regulation of the HBP between male and female 
db/db mice. This means that our Western blotting results are only preliminary 
and more experiments would have to be performed to confirm this result.  
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Future Studies 
 
• We are currently performing real-time PCR on RNA extracted from 
transfected myoblasts to determine whether the increase in ACCβ 
promoter activity results in a concomitant increase in endogenous RNA 
expression.  
 
• We will also be performing additional USF transfection experiments and 
DNA binding assays (ELISAs and CHiP) to confirm the role of USF1 and 
USF2 in the transcriptional regulation of ACCβ.  
 
• We would also like to confirm our L-glutamine transfection experiments by 
administering different doses of glucosamine to transfected myoblasts. 
Since it is more potent than L-glutamine, we expect to see a greater effect 
on ACCβ promoter activity.  
 
• We are also currently investigating an additional inhibitor, i.e. O-(2-
acetamido-2-deoxy-D-glucopyranosylidene) amino-N-phenylcarbamate 
(PUGNAc) (132), proposed to be more potent than streptozotocin.  
 
• We also intend to probe heart tissues from various type-2 diabetic rodent 
models (db/db, Zucker and diet-induced rat model). 
 
• To investigate our secondary hypothesis we will measure fatty acid 
accumulation with oil red staining and measure malonyl-CoA levels (Figure 
30).  
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Appendix 1: Preparation of modified RIPA buffer 
 
Preparation notes: 
 
Label eppendorf tubes (±98).  
Be sure to keep all inhibitors on ice and to add them last as indicated in the 
protocol. 
Many of the reagents have been made up before use.  
 
For 100ml modified RIPA buffer: 
 
1. Prepare 50 mM Tris-HCl (a buffering agent that prevents protein 
denaturation): 
•  Add 790 mg Tris to 75 ml distilled H20. Add 900 mg NaCl and stir. 
pH to 7.4 using HCl. 
 
2. Add 10 ml of 10% NP-40 to the solution. (Made up previously) 
 
3. Add 2.5 ml of 10% Na-deoxycholate (an ionic detergent to extract protein, 
protect from light) and stir. (Made up previously in H20) 
 
4. Add 1 ml 100 mM EDTA pH 7.4 (Acts as a calcium chelator). (Made up 
previously) 
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5. Now add the following protease inhibitors: 
• Phenylmethylsulfonyl flouoride (PMSF) – 200 mM stock made up in 
isopropanol and stored at room temperature (extremely short half 
life in aqueous solutions) 
• Leupeptin (1 mg/ml in H20) 
• SBT1 (5 mg/ml in H20) 
• Benzamidine (1 M) 
 
(All of the above are stored in the freezer with the exception of PMSF which is 
available as a stock) 
 
6. Add the following protease phosphatase inhibitors: 
• Activated Na3VO4 – 200 mM stock made up in H2O (stored in 
freezer along with the protease inhibitors) 
• NaF (200 mM stock) – (Made up previously) 
 
(Note: Do not at phosphatase inhibitors if lysates are to be used for 
phosphatase assays) 
 
7. Add 1 ml of Triton X-100. 
 
8. Make up to 100 ml with distilled H2O using a graduated cylinder. 
 
9. Aliquot 1 ml of RIPA buffer into each eppendorf tube before finally storing 
at -20°C 
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Final concentrations: 
 
• Tris-HCl: 50 mM 
• NP-40: 1% 
• Na-deoxycholate: 0.25% 
• EDTA: 1 mM 
• PMSF: 1 mM 
• Leupeptin: 1 µg/ml 
• SBT1: 4 µg/ml 
• Benzamidine: 1 mM 
• Na3VO4: 1 mM 
• NaF: 1 mM 
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Appendix 2: Bradford protein quantification and sample 
preparation 
 
Bradford reagent (5x concentrated): 
Dilute 500 mg of Coomassie Brilliant blue G in 250 ml 95% ethanol. 
Add 500 ml of phosphoric acid before mixing thoroughly. 
Make up to one liter with distilled H2O (dH2O). 
Filter and store at 4°C. 
 
Bradford working solution: 
Dilute stock in a 1:5 ratio with dH2O. 
Filter using 2 filter papers (at the same time). 
Solution should be a light brown color. 
 
Bradford method: 
• Thaw 1 mg/ml BSA stock solution. 
• Thaw protein samples if in -80°C freezer. Keep on ice at all times. 
• Make up a working solution of 100 µl BSA:400 µl dH2O. Vortex 
mixture. 
• Mark 7 microfuge tubes for the standards as well as tubes for the 
samples to be tested. 
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• Now add BSA and water to marker microfuge tubes as follows: 
  
 
Blank: 0 µl BSA 100 µl dH2O 
2 µl protein: 10 µl BSA 90 µl dH2O 
4 µl protein: 20 µl BSA 80 µl dH2O 
8 µl protein: 40 µl BSA 60 µl dH2O 
12 µl protein: 60 µl BSA 40 µl dH2O 
16 µl protein: 80 µl BSA 20 µl dH2O 
20 µl protein: 100 µl BSA 0 µl dH2O 
Each sample: 0 µl BSA 95 µl H20 5 µl of 
sample 
protein 
 
 
• Briefly vortex all the tubes. 
• Now add 900 µl of Bradford reagent to each microfuge tube. Vortex 
again. 
• Let the solutions stand for ~5 minutes (switch on the 
spectrophotometer in the meantime). 
• Read absorbencies, twice each, at 595 nm. 
o If sample values fall outside the range of the highest 
standard then dilute with RIPA buffer. 
• Make use of Excel to make a linear plot of absorbencies and then 
calculate the amount of each sample to be added to aliquots. 
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Sample preparation: 
 
• Begin by setting beaker of water to boil. 
o Remember to keep protein samples on ice at this point. 
• Make up a stock solution containing 850 µl of sample buffer and 
150 µl of mercaptoethanol. 
• Vortex the solution. 
• Calculate the number of sample sets needed, each containing one 
representative of each protein sample. 
• Add sample buffer to each aliquot (do so under the fume hood to 
avoid exposure to harmful fumes). 
• Add a volume of sample buffer equal to 1/3 of the final volume. 
• Now add the amount of sample calculated previously to each 
respective microfuge tube. 
• Punch small pin size holes in each tube then place in boiling water 
to stand for a period of 5 minutes. 
• Spin tubes for a moment (~5 seconds) using the tabletop centrifuge. 
• Samples can now be stored at -80°C. 
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Use of samples: 
 
In the case that samples have been stored in the -80°C freezer: 
 
• Start by bringing a beaker of water to the boil. 
• Remove samples from the freezer. 
• Make sure that small pin size holes have been punched in the top 
of each tube. 
• Place in boiling water for a period of 5 minutes. 
• Spin down momentarily (20 seconds) on the tabletop centrifuge 
(take care not to over centrifuge, especially if samples have been 
obtained from tissue. 
• Samples can now be used for Western blotting. 
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Appendix 3: Electrotransfer of proteins (Semi-dry apparatus) 
 
Solutions for PVDF membrane 
 
Anode buffer 1: 
0.3 M Tris-base, pH 10.4 
20% methanol 
 
Anode buffer 2: 
25 mM Tris-base, pH 10.4 
20% Methanol 
 
Cathode buffer: 
25 mM Tris-base 
40 mM ε-aminohexanoic acid 
pH to 9.4 
Add 20% methanol 
 
Need 8 Whatman 3MM papers and 1 PVDF membrane per gel cut to the 
required size. 
 
1. Soak PVDF membrane in methanol for 15 seconds. Put the membrane 
in slowly, allowing it to soak by osmosis and prevent air bubbles from 
being trapped. 
 
2. Soak 3 Whatman papers in anode buffer 1. 
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3. Soak 1 Whatman paper in anode buffer 2. 
 
4. Soak 4 Whatman paper in cathode buffer. 
 
5. On the anode plate of the semi-dry apparatus put the 3 papers from 
step 2 (anode 1), roll with a glass tube. 
 
6. Add 1 paper from step 3 (anode 2) and roll, making sure to remove 
bubbles. 
 
7. Add the PVDF membrane and roll gently. 
 
8. Take the gel with the proteins that have been electrophoresed and 
soak it in anode buffer 2. After soaking the gel, place it on top of the 
PVDF membrane. 
 
9. Roll the gel with a wet tube making sure remove any bubbles. 
 
10. Add the 4 Whatman papers from step 4 (cathode) on top of the gel and 
roll it with the glass tube. 
 
11. Close the apparatus with the lid and set it to transfer for 1 hour at 15 
volts and a current of 0.5 A. 
 
12. After the electrotransfer is complete fix the protein to the PVDF 
membrane by placing it in methanol for a few seconds 
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Appendix 4: O-GlcNAc Western blotting and detection 
 
Note: The following description is reproduced as supplied by the O-GlcNAc 
Western blot detection kit (Pierce, catalogue number 24565, Rockford, 
Illinois). 
 
Material Preparation:  
(All reagents are supplied in the O-GlcNAc Western blot Detection Kit) 
 
Wash Buffer Reconstitute one BupH™ Phosphate Buffer Saline 
(PBS) pack with 500 ml of ultrapure water and add 
2.5 ml of 10% Tween®-20 for a final concentration 
of ~0.05%. 
 
Blocking Buffer Dilute the 10x “Dilution buffer” (also functions as 
blocking buffer) to 1x in Wash buffer (e.g. 1 ml of 
10x Dilution Buffer to 9 ml of Wash buffer). 
 
Goat Anti-Mouse IgM 
-HRP Conjugate Prepare a 1 mg/ml stock solution by reconstituting 
the antibody in 75 µl of ultrapure water. Aliquot 6 µl 
the secondary antibody into separate micofuge 
tubes and add an equal volume of glycerol per 
aliquot. Store the aliquots at -20°C. By adding 
glycerol the final concentration of each aliquot 
changes to 0.5 mg/ml.  
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Procedure:  
1.  Remove PVDF membrane from the transfer apparatus and block 
nonspecific sites on the membrane by completely immersing the 
membrane with the blocking membrane (approximately 50 ml) at room 
temperature (RT) overnight at 4°C. 
 
2. Prepare a 1:5,000 dilution of the anti-O-GlcNAc monoclonal antibody in 
blocking buffer.  
 
3. Remove blocking buffer and add ~ 30 ml of the diluted antibody to the 
membrane. Incubate the blot overnight at 4°C.  Alternatively, we used 2 
µl of primary antibody in 10 ml of blocking buffer in a 50 ml Falcon tube 
and left the membrane to incubate overnight at 4°C. 
 
4. Wash the membrane six times by completely immersing in wash buffer 
(approximately 50 ml) and shaking for 5 minutes. 
 
5. Prepare a 10 µg/ml secondary antibody solution by diluting the 0.5 
mg/ml stock solution 1:100 in blocking buffer. Prepare approximately 
30 ml of a 1:5,000 dilution of the 10 µg/ml goat anti-mouse IgM-HRP in 
blocking buffer. For 30 ml of blocking buffer we added 12 µl of 
secondary antibody. 
 
6. Remove wash buffer, add the diluted secondary antibody and incubate 
for 1 hour at room temperature with gentle shaking.  
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7. Wash the membrane 6 times by completely immersing the membrane 
in wash buffer (approximately 50 ml) and shaking for 5 minutes. 
 
8. Prepare SuperSignal® West Dura Working Solution by mixing 5 ml of 
the Stable Peroxide Solution and 5 ml of the Luminol/Enhancer 
solution. Apply working solution to the membrane and incubate for 5 
minutes at room temperature. Use 0.125 ml substrate solution per cm2 
of membrane. 
 
9. Remove membrane from working solution and place in a plastic 
membrane protector. (We used two pieces of acetate).  
 
10. Place the protected membrane in a film cassette with the protein side 
facing up.  
 
11. The membrane was exposed to Hyperfilm (Amersham, 
Buckinghamshire, UK) in a dark room for up to 7 seconds and then 
placed in developer for ± 30 seconds. The film was washed and fixed.   
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Appendix 5: GFAT Western blotting and detection 
 
Buffers used: 
 
10x Tris Buffer Saline (TBS): (5 litres) 
121 g Tris 
40 g NaCl 
pH solution to 7.6 
 
TBS-T Wash Buffer Add 10 ml of 10x TBS to 90 ml of ultrapure or 
distilled water and then add 1 ml of Tween-20. 
 
Blocking Buffer Add 5 mg of milk powder (Elite skim milk powder) 
to 100 ml of TBS-T. 
 
Procedure: 
 
1. Remove PVDF (Millipore, Billerica, USA) membrane from the transfer 
apparatus and wash the membrane 3 times with TBS-T for 5 minutes. 
 
2. Block nonspecific sites on the membrane by completely immersing the 
membrane with the blocking membrane (approximately 50 ml) at room 
temperature (RT) overnight at 4°C. 
 
3. Prepare a 1:3,000 dilution of the GFAT antibody in blocking buffer.  
Stellenbosch University  http://scholar.sun.ac.za
 110 
4. Incubate the blot overnight at 4°C. We used 17 ul of primary antibody 
in 5 ml of blocking buffer in a 50 ml Falcon tube and left the membrane 
to incubate overnight at 4°C. 
 
5. Wash the membrane six times by completely immersing in TBS-T wash 
buffer (approximately 50 ml) and agitating for 5 minutes. 
 
6. Prepare approximately 1:2,000 dilution of goat anti-rabbit-horse radish 
peroxidase in blocking buffer. For 5 ml of blocking buffer we added 5 µl 
of secondary antibody. 
 
7. Remove wash buffer, add the diluted secondary antibody and incubate 
for 1 hour at room temperature with gentle shaking.  
 
8. Wash the membrane six times by completely immersing the membrane 
in TBS-T wash buffer (approximately 50 ml) and shaking for 5 minutes. 
 
9. Wash the membrane for 15 minutes with TBS. 
 
10.  Add 0.5 ml of ECL Reagent 1 to the membrane and then add ECL 
reagent 2 to the membrane. Make sure to spread the ECL reagents 
over the whole membrane. Incubate for 1 minute at room temperature 
while continuously washing the ECL reagent mixture over the 
membrane. 
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11. Remove membrane from ECL reagent and place in a plastic 
membrane protector (we used two pieces of acetate).  
 
12. Place the protected membrane in a film cassette with the protein side 
facing up.  
 
13. The membrane was exposed to Hyperfilm (Amersham, 
Buckinghamshire, UK) in a dark room for up to ± 7 minutes and then 
placed in developer for ± 30 seconds. The film was washed and fixed.   
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Appendix 6: β-Actin Western blotting and detection 
 
Buffers used: 
 
TBS-T Wash Buffer Add 10 ml of 10x TBS to 90 ml of ultrapure or 
distilled water and then add 1 ml of Tween-20. 
 
Blocking Buffer Add 5 mg of milk powder (Elite skim milk powder) 
to 100 ml of TBS-T. 
 
Procedure: 
 
1. Remove PVDF (Millipore, Billerica, USA) membrane from the transfer 
apparatus and wash the membrane 3 times with TBS-T for 5 minutes. 
 
2. Block nonspecific sites on the membrane by completely immersing the 
membrane with the blocking membrane (approximately 50 ml) at room 
temperature (RT) overnight at 4°C. 
 
3. Prepare a 1:1,000 dilution of the anti-β-Actin monoclonal antibody (Cell 
Signaling, Danvers, MA, USA) in blocking buffer.  
 
4. Incubate the blot overnight at 4°C. We used 5 µl of primary antibody in 
5 ml of blocking buffer in a 50 ml Falcon tube and left the membrane to 
incubate overnight at 4°C. 
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5. Wash the membrane five times by completely immersing in TBS-T 
wash buffer (approximately 50 ml) and agitating for 5 minutes. 
 
6. Prepare approximately 1:2,000 dilution of goat anti-rabbit-horse radish 
peroxidase in blocking buffer. For 5 ml of blocking buffer we added 5 µl 
of secondary antibody. 
 
7. Remove wash buffer, add the diluted secondary antibody and incubate 
for 1 hour at room temperature with gentle shaking.  
 
8. Wash the membrane 3 times by completely immersing the membrane 
in TBS-T wash buffer (approximately 50 ml) and agitating for 5 
minutes. 
 
9. Wash the membrane for 15 minutes with TBS. 
 
10.  Add 0.5 ml of ECL reagent 1 to the membrane and then add ECL 
reagent 2 to the membrane. Make sure to spread the ECL reagents 
over the whole membrane. Incubate for 1 minute at room temperature 
while continuously washing the ECL reagent mixture over the 
membrane. 
 
11. Remove membrane from ECL reagent and place in a plastic 
membrane protector (we used two pieces of acetate).  
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12. Place the protected membrane in a film cassette with the protein side 
facing up.  
 
13. The membrane was exposed to Hyperfilm (Amersham, 
Buckinghamshire, UK) in a dark room for up to ± 7 minutes and then 
placed in developer for ± 30 seconds. The film was washed and fixed.   
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Appendix 7: Stripping protocol 
 
1. Make up the following solution: 
100 mM β-Mercaptoethanol: 700 ml/100 ml 
2% SDS: 20 ml/100 ml (from 10% stock) 
62.5 mM Tris-HCl pH 6.7: 0.757 g/100 ml 
Make up to 100 ml with H20 
  
2. Incubate membrane in solution at 60°C for 30-60 min with occasional 
agitation. 
 
3. Wash the membrane in TBS-Tween before blocking in 5% milk. 
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